高血压治疗药依普利酮怎么样

Hypertension is a common circulatory system disease with a high incidence rate, especially among middle-aged and elderly people. (eplerenone) is the first selective aldosterone receptor antagonist. It has been used to treat hypertension and left ventricular dysfunction after acute myocardial infarction. It can effectively lower blood pressure, improve cardiac function, and reduce myocardial damage.

Therapeutic effects of eplerenone:

Studies have shown that eplerenone can cause a sustained increase in plasma renin and serum aldosterone, and at the same time block the feedback regulatory effect of aldosterone. However, the increase in plasma renin activity and the increase in systemic circulation aldosterone levels will not offset the blood pressure control effect of this product. Eplerenone and spironolactone work on the same principle. Long-term use of spironolactone can cause endocrine disorders, while eplerenone has good tolerance and has the advantage of less side effects, avoiding the side effects of endocrine disorders.

Eplerenone treats patients with stage 1 and stage 2 hypertension with similar efficacy rates and reductions in systolic and diastolic blood pressure as enalapril. Eplerenone also has a good antihypertensive effect in patients with essential hypertension with low renin levels for whom angiotensin-converting enzyme inhibitors and angiotensin II receptor inhibitors are not effective. It also has a good antihypertensive effect on simple systolic hypertension, and has a good antihypertensive effect on diet-induced obesity-related hypertension. In addition, eplerenone can significantly reduce the ultrafiltration effect of glomeruli and reduce albuminuria in patients with hypertension. This renal protective effect is more obvious for hypertensive patients with diabetes.

To sum up, the effect of treating high blood pressure is very obvious, it can effectively reduce blood pressure, and it is safer. It is a good choice for patients with high blood pressure.

Recommended related hot articles: /newsDetail/79927.html